Compare Neurocrine Biosciences Inc (NBIX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PAGSEG Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while PAGSEG Inc trades at $9.6 (market cap $2.69B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.9× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.49% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PAGS | |
|---|---|---|
Market Cap | $15.77B | $2.69B |
Sector | Health | Technology |
52-Week High | $185.50 | $12.00 |
52-Week Low | $123.10 | $8.44 |
Enterprise Value | $15.78B | $10.60B |
Dividend Yield | — | 11.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PAGS trades at $9.75, up 0.21% today, with a bullish technical signal from moving averages and a consensus analyst price target of $11.45. The company reported Q2 2026 EPS of $0.41, beating expectations, and maintains solid fundamentals with a P/E of 6.67 and net income margin of 10.45%. Recent news highlights institutional investments and management continuity despite leadership changes.
The outlook is positive with attractive valuation and growth potential, but risks include macroeconomic challenges in Brazil and competitive pressures. Upside is supported by analyst buy ratings and dividend payments, though investors should monitor credit loss trends and interest rate impacts on profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
